|
시장보고서
상품코드
2055012
무좀 치료제 시장 : 약제 클래스별, 투여 경로별, 제형별, 처방 형태별, 연령층별, 감염 유형별, 유통 채널별, 최종사용자별, 지역별Tinea Pedis Treatment Market, By Drug Class, By Route of Administration, By Formulation, By Prescription Type, By Age Group, By Infection Type, By Distribution Channel, By End User, By Geography |
||||||
무좀 치료 시장은 2026년에 16억 6,000만 달러로 추정되며, 2033년까지 28억 7,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 8.1%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 16억 6,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 8.10% | 2033년 시장 규모 예측 : | 28억 7,000만 달러 |
세계 무좀 치료 시장은 피부과 치료제 업계에서 중요한 부분을 차지하고 있으며, 전 세계 수백만 명에게 영향을 미치는 가장 흔한 진균 감염증 중 하나를 다루고 있습니다. 무좀(일반적으로 무좀으로 알려져 있음)은 주로 적모사균(Trichophyton rubrum), 백색모사균(Trichophyton mentagrophytes), 그리고 솜털모양표피사균(Epidermophyton floccosum) 등의 피부사균에 의해 유발되는 표재성 진균 감염증입니다.
이 질환은 발의 피부, 특히 발가락 사이에 영향을 미치며, 가려움증, 작열감, 각질부터 수포나 이차적인 세균 감염과 같은 더 심각한 증상에 이르기까지 다양한 증상을 유발합니다. 치료법에는 테르비나핀, 클로트리마졸, 미코나졸 등의 외용 항진균제 외에도, 중증 사례나 재발 사례에 대한 전신 투여 약물 등 다양한 치료법이 포함됩니다. 이 시장의 성장 추세는 발 위생에 대한 인식 제고, 라이프스타일 변화로 인한 진균 감염 발생률 증가, 스포츠 활동 참여 확대, 신흥국에서의 의료 접근성 확대 등의 요인에 의해 영향을 받고 있습니다. 의료진은 유효성, 안전성 및 환자의 치료 순응도를 우선시하는 근거 기반 치료 프로토콜을 따르며, 치료 기간은 일반적으로 감염의 중증도나 선택된 치료법에 따라 2주에서 6주 사이입니다.
시장 역학
세계 무좀 치료 시장은 다양한 지역의 성장 전망을 종합적으로 강화하는 몇 가지 강력한 시장 성장 촉진요인에 힘입어 성장하고 있습니다. 주요 성장 요인은 스포츠 및 피트니스 활동 참여 증가, 공공시설의 공동 사용으로 이어지는 도시화, 그리고 곰팡이 증식에 적합한 환경을 조성하는 생활 방식의 변화로 인한 전 세계 무좀 감염률의 상승에 있습니다. 의료비 증가와 진단 능력의 향상으로 조기 발견과 조기 치료가 가능해졌으며, 한편으로는 발 건강 및 위생에 관한 인식 제고 캠페인의 확대가 전문적인 의료 개입을 원하는 환자들의 행동을 뒷받침하고 있습니다. 면역 기능 저하 및 동반 질환으로 인해 진균 감염에 대한 감수성이 높은 고령 인구 증가 또한 시장 수요를 더욱 확대시키고 있습니다.
그러나 시장에는 중대한 제약도 존재합니다. 그 중 하나는 환자들이 자가 치료를 위해 즐겨 사용하는 일반의약품의 접근성인데, 이는 전문적인 치료의 지연을 초래하고 처방약 매출을 감소시킬 가능성이 있습니다. 또한, 치료 기간이 길다는 점과 경미한 감염증이 무증상이라는 점으로 인해 치료 지침을 준수하지 않는 경우도 시장의 지속적인 성장에 있어 또 다른 과제로 대두되고 있습니다. 항진균제 승인에 관한 규제의 강화와 약물 내성 진균주의 출현은 새로운 치료법을 개발하는 제약 기업들에게 장애물이 되고 있습니다. 한편, 환자의 복약 순응도와 치료 성과를 향상시키는 네일 래커, 서방형 제제, 병용 요법 등 혁신적인 약물 전달 시스템의 개발에는 큰 기회가 존재합니다. 신흥 시장, 특히 아시아태평양과 라틴아메리카의 미개척 잠재력은 의료 인프라 개선, 가처분 소득 증가, 그리고 사람들의 건강 의식 고취에 힘입어 수익성 높은 성장 기회를 제공합니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 주요 지표를 바탕으로 전 세계 무좀 치료 시장의 주요 기업들을 분석했습니다. 기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적 및 전략.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 ‘세계 무좀 치료 시장 보고서’는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 무좀 치료 시장을 분석하는 데 활용되는 다양한 전략 매트릭스를 통해 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 무좀 치료제 시장 : 약제 클래스별, 2021년-2033년
제5장 세계의 무좀 치료제 시장 : 투여 경로별, 2021년-2033년
제6장 세계의 무좀 치료제 시장 : 제제별, 2021년-2033년
제7장 세계의 무좀 치료제 시장 : 처방 유형별, 2021년-2033년
제8장 세계의 무좀 치료제 시장 : 연령층별, 2021년-2033년
제9장 세계의 무좀 치료제 시장 : 감염 유형별, 2021년-2033년
제10장 세계의 무좀 치료제 시장 : 유통 채널별, 2021년-2033년
제11장 세계의 무좀 치료제 시장 : 최종사용자별, 2021년-2033년
제12장 세계의 무좀 치료제 시장 : 지역별, 2021년-2033년
제13장 경쟁 구도
제14장 애널리스트의 제안
제15장 참고 문헌 및 조사 방법
LSH 26.06.19Tinea Pedis Treatment Market is estimated to be valued at USD 1.66 Bn in 2026 and is expected to reach USD 2.87 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1.66 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.10% | 2033 Value Projection: | USD 2.87 Bn |
The global tinea pedis treatment market represents a significant segment within the dermatological therapeutics industry, addressing one of the most prevalent fungal infections affecting millions worldwide. Tinea pedis, commonly known as athlete's foot, is a superficial fungal infection caused primarily by dermatophytes including Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum.
This condition affects the skin of the feet, particularly between the toes, causing symptoms ranging from itching, burning, and scaling to more severe manifestations including blisters and secondary bacterial infections. The treatment landscape encompasses various therapeutic modalities including topical antifungals such as terbinafine, clotrimazole, and miconazole, as well as systemic medications for severe or recurrent cases. The market's growth trajectory is influenced by factors including increasing awareness of foot hygiene, rising incidence of fungal infections due to lifestyle changes, growing participation in sports activities, and expanding healthcare access in emerging economies. Healthcare providers rely on evidence-based treatment protocols that prioritize efficacy, safety, and patient compliance, with treatment duration typically ranging from two to six weeks depending on infection severity and chosen therapeutic approach.
Market Dynamics
The global tinea pedis treatment market is propelled by several robust drivers that collectively strengthen its growth prospects across diverse geographical regions. The primary growth driver stems from the escalating global prevalence of tinea pedis infections, attributed to increased participation in sports and fitness activities, urbanization leading to shared public facilities usage, and lifestyle modifications that create favorable conditions for fungal proliferation. Rising healthcare expenditure and improved diagnostic capabilities enable earlier detection and treatment initiation, while growing awareness campaigns about foot health and hygiene drive patient seeking behavior for professional medical intervention. The expanding geriatric population, who demonstrate higher susceptibility to fungal infections due to compromised immune systems and comorbidities, further amplifies the market demand.
However, the market faces significant restraints including the availability of over-the-counter alternatives that patients often prefer for self-medication, potentially delaying professional treatment and reducing prescription medication sales. Treatment non-compliance due to lengthy therapeutic regimens and the asymptomatic nature of mild infections pose additional challenges to sustained market growth. Regulatory stringency regarding antifungal drug approvals and the emergence of drug-resistant fungal strains create barriers for pharmaceutical companies developing new therapeutic solutions. Conversely, substantial opportunities exist in the development of innovative drug delivery systems including nail lacquers, sustained-release formulations, and combination therapies that enhance patient compliance and treatment outcomes. The untapped potential in emerging markets, particularly in Asia Pacific and Latin America, presents lucrative expansion opportunities driven by improving healthcare infrastructure, rising disposable incomes, and increasing health consciousness among populations.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global tinea pedis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Bayer AG, Novartis AG, Sandoz Group, Teva Pharmaceutical Industries Ltd, Viatris Inc, Sun Pharmaceutical Industries Ltd, Taro Pharmaceutical Industries Ltd, Galderma SA, Bausch Health Companies Inc, Perrigo Company plc, Dr Reddy's Laboratories Ltd, Glenmark Pharmaceuticals Ltd, Cipla Ltd, Zydus Lifesciences Ltd, and Sanofi Consumer Healthcare
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global tinea pedis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tinea pedis treatment market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Allylamines and Benzylamines (e.g., terbinafine, naftifine, etc.)
- Azoles (e.g., clotrimazole, miconazole, etc.)
- Hydroxypyridones (e.g., ciclopirox)
- Morpholines (e.g., amorolfine)
- Others (e.g., tolnaftate, undecylenic acid)
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Topical
- Oral
- Formulation Insights (Revenue, USD Bn, 2021 - 2033)
- Creams and Ointments
- Sprays
- Powders
- Gels
- Tablets
- Capsules
- Solution
- Prescription Type Insights (Revenue, USD Bn, 2021 - 2033)
- Over-the-counter (OTC)
- Prescription (Rx)
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Pediatric
- Adult
- Infection Type Insights (Revenue, USD Bn, 2021 - 2033)
- Interdigital
- Moccasin (chronic hyperkeratotic)
- Vesiculobullous
- Ulcerative
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Dermatology Clinics
- Homecare Settings
- Outpatient/Primary care
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Bayer AG
- Novartis AG
- Sandoz Group
- Teva Pharmaceutical Industries Ltd
- Viatris Inc
- Sun Pharmaceutical Industries Ltd
- Taro Pharmaceutical Industries Ltd
- Galderma SA
- Bausch Health Companies Inc
- Perrigo Company plc
- Dr Reddy's Laboratories Ltd
- Glenmark Pharmaceuticals Ltd
- Cipla Ltd
- Zydus Lifesciences Ltd
- Sanofi Consumer Healthcare
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Tinea Pedis Treatment Market, By Drug Class
- Global Tinea Pedis Treatment Market, By Route of Administration
- Global Tinea Pedis Treatment Market, By Formulation
- Global Tinea Pedis Treatment Market, By Prescription Type
- Global Tinea Pedis Treatment Market, By Age Group
- Global Tinea Pedis Treatment Market, By Infection Type
- Global Tinea Pedis Treatment Market, By Distribution Channel
- Global Tinea Pedis Treatment Market, By End User
- Global Tinea Pedis Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Tinea Pedis Treatment Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Allylamines and Benzylamines (e.g., terbinafine, naftifine, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Azoles (e.g., clotrimazole, miconazole, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Hydroxypyridones (e.g., ciclopirox)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Morpholines (e.g., amorolfine)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (e.g., tolnaftate, undecylenic acid)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Tinea Pedis Treatment Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Tinea Pedis Treatment Market, By Formulation, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Creams and Ointments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Sprays
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Powders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Gels
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Solution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Tinea Pedis Treatment Market, By Prescription Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Over-the-counter (OTC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Prescription (Rx)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Tinea Pedis Treatment Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Tinea Pedis Treatment Market, By Infection Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Interdigital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Moccasin (chronic hyperkeratotic)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Vesiculobullous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ulcerative
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Tinea Pedis Treatment Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Tinea Pedis Treatment Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Dermatology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Outpatient/Primary care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
12. Global Tinea Pedis Treatment Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Infection Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Infection Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Infection Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Infection Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Infection Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Infection Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sandoz Group
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Taro Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Galderma SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bausch Health Companies Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Perrigo Company plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr Reddy's Laboratories Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zydus Lifesciences Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi Consumer Healthcare
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About Us
